Research programme: ELOVL6 inhibitors - Banyu
Latest Information Update: 16 Jul 2016
At a glance
- Originator Banyu
- Class Indoles; Pyrazoles
- Mechanism of Action ELOVL6 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in Japan (PO)
- 09 Jun 2009 Preclinical trials in Diabetes mellitus in Japan (PO)